194 completed. 194 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 194 | Completed 194 |
Follow Neurodevelopmental Disorders: new trials by email Literature Review of Neurodevelopmental Disorders trials Research Report on Neurodevelopmental Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Open-label Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD and Mood Symptoms SPN-812 - Attention-Deficit/Hyperactivity Disorder | Phase 4 | Completed | Supernus Pharmaceuticals, Inc. | 161 | 2024-03-25 | 2026-03-27 |
| Duration and Efficacy of Azstarys on Adult ADHD Symptoms and Executive Function in Early Evening Serdexmethylphenidate/dexmethylphenidate - Adult Attention Deficit Hyperactivity Disorder | Phase 4 | Completed | NYU Langone Health | 29 | 2023-11-13 | 2025-07-29 |
| Impact of Motor Tasks and Lidocaine on Reading Unfamiliar Words in Adults With and Without Dyslexia Lidocaine 2% Polyampoule - Reading Disorders | Phase 4 | Completed | University of Alberta | 56 | 2023-08-24 | 2026-02-05 |
| A Safety/Tolerability and PK Study With Azstarys® in Children With ADHD Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH) - Attention Deficit/Hyperactivity Disorder | Phase 4 | Completed | Corium, Inc. | 123 | 2023-06-02 | 2026-05-08 |
| An Efficacy and Safety Study w/ Azstarys® in Children 4-12 Years of Age With ADHD Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH), placebo - Attention Deficit/Hyperactivity Disorder | Phase 4 | Completed | Corium, Inc. | 246 | 2023-03-22 | 2025-05-13 |
| Biomarker-Driven Pharmacological Treatment of Adolescents With Autism Spectrum Disorder With Gabapentin Gabapentin - Autism Spectrum Disorder | Phase 4 | Completed | David Cochran | 16 | 2022-02-04 | 2026-02-20 |
| Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole Comparison of Risperidone and Aripiprazole - Weight Gain, Autism Spectrum Disorder | Phase 4 | Completed | Vanderbilt University Medical Center | 30 | 2022-02-01 | 2026-10-05 |
| Open-Label Study of SPN-812 Administered With Psychostimulants in Children and Adolescents With ADHD SPN-812 - Attention-Deficit/Hyperactivity Disorder (ADHD) | Phase 4 | Completed | Supernus Pharmaceuticals, Inc. | 96 | 2021-07-27 | 2024-05-01 |
| Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome Guanfacine Extended Release, Placebo - Prader-Willi Syndrome, Aggression | Phase 4 | Completed | Maimonides Medical Center | 15 | 2020-12-17 | 2024-08-19 |
| Brain Indices of Stimulant Treatment in Drug-Naive Youth at Risk for Substance Use Disorder Adderall - Attention Deficit Disorder With Hyperactivity, Conduct Disorder | Phase 4 | Completed | Jeffrey Newcorn | 33 | 2019-11-05 | 2024-08-29 |
| Real World Evidence of the Efficacy and Safety of FOQUEST Methylphenidate Hydrochloride, Lisdexamfetamine Dimesylate - Attention Deficit-Hyperactivity Disorder | Phase 4 | Completed | Purdue Pharma, Canada | 257 | 2019-09-19 | 2021-09-16 |
| A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD) Guanfacine hydrochloride (TAK-503), Atomoxetine hydrochloride, Placebo - Attention Deficit Hyperactivity Disorder | Phase 4 | Completed | Shire | 396 | 2019-09-18 | 2026-04-13 |
| Natural Treatments for the Management of Emotional Dysregulation in Youth With Non-verbal Learning Disability (NVLD) and/or Autism Spectrum Disorders (ASD) Open-label Treatment with Omega-3 Fatty Acids + Inositol, Open-label Treatment with N-acetylcysteine - Non-verbal Learning Disorder, Autism Spectrum Disorder | Phase 4 | Completed | Massachusetts General Hospital | 54 | 2019-05-20 | 2025-06-05 |
| A 14 Week, Randomized, Placebo-Controlled Cross-Over Study of Methylphenidate Hydrochloride Controlled Release Capsules in Adult ADHD With and Without Anxiety Disorder Comorbidity Methylphenidate Hydrochloride Controlled-Release Capsules, Placebo Capsule - Attention Deficit Hyperactivity Disorder, Generalized Anxiety Disorder | Phase 4 | Completed | McMaster University | 60 | 2019-04-20 | 2023-10-26 |
| Improving Driving in Young People With Autism Spectrum Disorders Buspirone - Autism Spectrum Disorder | Phase 4 | Completed | Massachusetts General Hospital | 26 | 2018-10-31 | 2021-03-18 |
| Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism Lisdexamfetamine Dimesylate - Attention Deficit Hyperactivity Disorder, Autism Spectrum Disorder | Phase 4 | Completed | JPM van Stralen Medicine Professional | 48 | 2018-09-26 | 2024-02-12 |
| Pharmacokinetic Study of DYANAVEL XR (Amphetamine) Extended-release Oral Suspension, in Children Aged 4 to 5 Years Amphetamine Extended Release Suspension [Dyanavel] - Attention Deficit Hyperactivity Disorder | Phase 4 | Completed | Tris Pharma, Inc. | 5 | 2018-05-07 | 2019-06-25 |
| Efficacy of Lisdexamfetamine Dimesylate for Promoting Occupational Success in Young Adults With ADHD Lisdexamfetamine Dimesylate 40 MG, Placebo - Attention Deficit Disorder With Hyperactivity | Phase 4 | Completed | Gregory Fabiano | 22 | 2018-04-01 | 2021-06-24 |
| Promoting Positive Outcomes for Individuals With ASD: Linking Early Detection, Treatment, and Long-term Outcomes Enhanced early detection - Autism Spectrum Disorder | Phase 4 | Completed | Drexel University | 2087 | 2017-11-29 | 2024-08-16 |
| Effects of Ondansetron in Obsessive-compulsive and Tic Disorders Ondansetron, Placebo - Obsessive-Compulsive Disorder, Tic Disorders | Phase 4 | Completed | NYU Langone Health | 110 | 2017-06-16 | 2024-05-03 |
Showing 20 of 194. Sign in to see all of them.
Attention Deficit Disorder with Hyperactivity (153) · Autism Spectrum Disorder (16) · Autistic Disorder (14) · Substance-Related Disorders (7) · Conduct Disorder (6) · Tourette Syndrome (6) · Aggression (5) · Asperger Syndrome (5) · Bipolar Disorder (5) · Dyslexia (5) · Child Development Disorders, Pervasive (4) · Epilepsy (4) · Learning Disabilities (4) · Oppositional Defiant Disorder (4) · Spasm (4)
Mental Disorders (193) · Attention Deficit and Disruptive Behavior Disorders (155) · Nervous System Diseases (28) · Child Development Disorders, Pervasive (23) · Pathological Conditions, Signs and Symptoms (23) · Signs and Symptoms (23) · Neurologic Manifestations (20) · Central Nervous System Diseases (13) · Brain Diseases (12) · Autism Spectrum Disorder (10) · Behavior (10) · Chemically-Induced Disorders (9) · Communication Disorders (9) · Neurobehavioral Manifestations (9)
Methylphenidate (61) · Atomoxetine Hydrochloride (40) · Lisdexamfetamine Dimesylate (22) · Guanfacine (12) · Aripiprazole (9) · Risperidone (7) · Dexmethylphenidate Hydrochloride (5) · SLI381 (4) · Sugars (4) · 5,10-dihydro-5-methylphenazine (3) · Adderall (3) · Amphetamine (3) · Dextroamphetamine (3) · Fatty Acids, Omega-3 (3) · Naltrexone (3)
Eli Lilly and Company (21) · Massachusetts General Hospital (21) · NYU Langone Health (7) · Shire (7) · Children's Hospital Medical Center, Cincinnati (5) · New York State Psychiatric Institute (4) · Icahn School of Medicine at Mount Sinai (3) · National Institute of Mental Health (NIMH) (3) · Ortho-McNeil Janssen Scientific Affairs, LLC (3) · Seattle Children's Hospital (3) · University of Arizona (3) · Corium, Inc. (2) · Federal University of Rio Grande do Sul (2) · Florida International University (2) · JPM van Stralen Medicine Professional (2)
United States (136) · Canada (11) · Netherlands (9) · Germany (8) · Sweden (7) · Brazil (6) · Belgium (4) · Puerto Rico (4) · China (3) · South Korea (3) · Taiwan (3) · United Kingdom (3) · Hungary (2) · India (2) · Norway (2)
Joseph Biederman, MD (7) · Jeffrey Newcorn, MD (4) · Ann Childress, MD (3) · Paul Hammerness, MD (3) · Timothy Wilens, MD (3) · Eric Hollander, MD (2) · Gagan Joshi, MD (2) · Harvey S Singer, MD (2) · Jaswinder K Ghuman, M.D. (2)
PMID 25019647, PMID 37811711, PMID 21569378, PMID 28980198, PMID 10591283, PMID 10591284, PMID 10637676, PMID 10637677, PMID 11104313, PMID 11104315, PMID 11104317, PMID 11211363, PMID 11211364, PMID 11211365, PMID 11211366, PMID 11211367, PMID 11294072, PMID 12014781, PMID 12108764, PMID 12795577, PMID 12880507, PMID 14595084, PMID 14998110, PMID 15060225, PMID 15677282, PMID 15685125, PMID 15827573, PMID 16135621, PMID 16350601, PMID 16371674, PMID 16418159, PMID 16671928, PMID 16818861, PMID 16881772, PMID 17053977, PMID 17448997, PMID 17667478, PMID 17667479, PMID 17667480, PMID 17667481, PMID 17710545, PMID 18573923, PMID 18573924, PMID 18759644, PMID 19142107, PMID 19192455, PMID 19307987, PMID 19318991, PMID 19374023, PMID 19394037
2014 (3), 2015 (1), 2018 (1), 2019 (1), K23MH064975 (1), K23MH066127 (1), K23MH066835 (1), K23MH081285 (1), K23MH083881 (1), K24DA016264 (1), M01RR010710 (1), P30MH066386 (1), P50MH077248 (1), R00MH102349 (1), R01DA022284 (1)